Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma.
Follow-up data for 11 patients with non-Hodgkin's lymphoma treated with partially purified human leukocyte interferon is presented. The interferon preparation used was 0.1% pure and treatment consisted of 5 x 10(6) U given intramuscularly twice daily for 60 injections. One complete, three partial, and three minimal responses were observed in five of seven evaluable patients with nodular non-Hodgkin's lymphoma. Duration of response appears to be from 6 to 12 mo. One patient achieved a second partial response on retreatment with interferon in spite of having received chemotherapy in the interval between interferon treatments. No responses were seen in three patients with rapidly progressive diffuse histiocytic lymphoma. Dose-limiting toxicity is leukopenia, which necessitated modification or cessation of treatment in three patients. Nonhematologic toxicities consisted of fever, malaise, arthralgia, and loss of appetite. In conclusion, interferon has activity against non-Hodgkin's lymphoma, and prior treatment with chemotherapy does not preclude a response to interferon.
D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006098:Granulocytes; D006801:Humans; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use*; D007592:Joint Diseases / Q000209:etiology; D007958:Leukocyte Count; D007962:Leukocytes / Q000378:metabolism*; D007970:Leukopenia / Q000209:etiology; D008206:Lymphatic Diseases / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000209:etiology
D007372:Interferons